Alicyn坎贝尔

作为肿瘤学研究院数字健康部门的主管&澳门葡京网赌游戏的博士, my focus is on leveraging emerging technology to improve patient care and expand the evidence base for oncology treatments. I have deep experience in developing and implementing innovative patient relevant evidence strategies across tumour types within oncology drug development and rare disease.

我相信可靠的经验证据是授权决策的支柱. 我最热衷的是测量癌症的影响, 以及抗癌疗法的耐受性, 以严谨可靠的方式对待病人. This work is critical in providing patients with the best evidence to make important healthcare decisions, 比如治疗选择, 癌症诊断后.

作为战略咨询集团的创始人, 患者相关证据, I work to optimize patient-centric evidence generation for non-profit advocacy entities and academic consortiums. This includes recent work with the European organisation for the Treatment of cancer focused on the development of international standards in analysing patient-reported outcomes and quality of life endpoints for cancer clinical trials for regulatory evaluation.

最近, 我曾领导罗氏/基因泰克以患者为中心的肿瘤结果研究小组, in which I was responsible for novel Food and Drug Administration (FDA) patient-reported outcomes labelling claims on products for lymphoma and haemophilia. 另外, I developed the Symptoms in Lung Cancer tool while at Roche which was included in multiple front-line Phase 3 registration trials. 在那之前, I was a Director in Health Economics and Outcomes Research at Pfizer Oncology responsible for outcomes research strategy for the development pipeline.

在我的职业生涯中, 我一直是许多政策倡议的贡献者和顾问，例如具有里程碑意义的21^st 世纪治愈立法. I’ve participated in various FDA workshops and legislative briefings about the importance of the patient experience in drug development. I also served as co-chair of the Critical Path Institute’s Non-Small Cell Lung Cancer Working Group. 我的工作得到了前副总统拜登的癌症登月计划的认可.

I completed my Masters of Public Health from the University of Connecticut School of Medicine with concentrations in Epidemiology and Outcomes Research.